EXEL

EXEL

USD

Exelixis Inc. Common Stock

$37.900+0.090 (0.238%)

Prix en Temps Réel

Healthcare
Biotechnologie
États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$37.810

Haut

$38.900

Bas

$37.582

Volume

2.81M

Fondamentaux de l'Entreprise

Capitalisation Boursière

10.2B

Industrie

Biotechnologie

Pays

United States

Statistiques de Trading

Volume Moyen

2.62M

Bourse

NMS

Devise

USD

Intervalle sur 52 Semaines

Bas $31.9Actuel $37.900Haut $49.62

Actualités Connexes

BusinessWire

Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update

- Total Revenues of $597.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $542.9 million - - GAAP Diluted EPS of $0.69, Non-GAAP Diluted EPS of $0.78 - - Announced Additional Stock Repurchase Program for

Voir plus
Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Analyst Upgrades

Guggenheim Downgrades Exelixis to Neutral

Guggenheim analyst Michael W. Schmidt downgrades Exelixis from Buy to Neutral.

Voir plus
Guggenheim Downgrades Exelixis to Neutral
PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are...

Voir plus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
BusinessWire

Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2025 financial results will be released on Tuesday, November 4, 2025 after

Voir plus
Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
Analyst Upgrades

Morgan Stanley Maintains Overweight on Exelixis, Lowers Price Target to $44

Morgan Stanley analyst Sean Laaman maintains Exelixis with a Overweight and lowers the price target from $50 to $44.

Voir plus
Morgan Stanley Maintains Overweight on Exelixis, Lowers Price Target to $44
Analyst Upgrades

RBC Capital Reiterates Sector Perform on Exelixis, Maintains $45 Price Target

RBC Capital analyst Leonid Timashev reiterates Exelixis with a Sector Perform and maintains $45 price target.

Analyst Upgrades

Wells Fargo Maintains Equal-Weight on Exelixis, Lowers Price Target to $30

Wells Fargo analyst Derek Archila maintains Exelixis with a Equal-Weight and lowers the price target from $36 to $30.

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.